Abstract: The invention involves the use of formulations of allosteric modulators of primarily 5ht2/5ht1, glutamate or SERT serotonin transporter, but also those of: 5ht1a/b/c/d, 5ht2a/b/c, 5ht3, 5ht4, 5ht7, dopamine, GLP, and other receptors/systems, in combination with phenethylamines, tryptamines, ibogaloids as well as vaccines, antibodies and other compounds; to treat or reduce symptoms of anxiety, depression, attention deficiency (ADD), attention deficient hyperactivity (ADHD), obsessive compulsive (OCD), bipolar disorder, and related disorders/conditions.

Abstract: The invention involves the use of formulations of allosteric modulators of primarily 5ht2a/5ht1a, opiate or SERT serotonin transporter, but also those of: 5ht1a/b/c/d, 5ht2a/b/c, 5ht3, 5ht4, 5ht7, dopamine, GLP, and other receptors/systems, in combination with phenethylamines, tryptamines, ibogaloids as well as vaccines, antibodies and other compounds; to treat stimulant dependency (addiction).

Abstract: The invention involves the use of formulations of allosteric modulators of primarily 5ht2/tht1, CB1 and GLP-1 serotonin transporter, but also those of: 5ht1a/b/c/d, 5ht2a/b/c, 5ht3, 5ht4, 5ht7 and other receptors, in combination with vaccines/antibodies, and phenethylamines, tryptamines, ibogaloids and other compounds; to treat or reduce symptoms of ingestion of drugs such as cannabis or 5-ht2a agonists. The method of delivery/formulation selected from: Inhaler, nebulizer, intravenously, intramuscularly, injection, capsules, tablets, pills.

Abstract: The invention involves the use of formulations of allosteric modulators of primarily 5ht2/5ht1, opiate or SERT serotonin transporter, but also those of: 5ht1a/b/c/d, 5ht2a/b/c, 5ht3, 5ht4, 5ht7, dopamine, GLP, and other receptors/systems, in combination with phenethylamines, tryptamines, ibogaloids as well as vaccines, antibodies and other compounds; to treat opiate dependency (addiction). Wherein opiate means, any opiate compound/mixture/drug, including, but not limited to synthetic, semisynthetic, natural, such as but not limited to opium, morphine, heroin, codeine, oxycodone, fentanyl, methadone, or other.

Abstract: The invention involves the use of formulations of allosteric modulators of primarily 5ht2/tht1, CB1 and GLP-1 serotonin transporter, but also those of: 5ht1a/b/c/d, 5ht2a/b/c, 5ht3, 5ht4, 5ht7 and other receptors, in combination with phenethylamines, tryptamines, ibogaloids and other compounds; to treat or reduce symptoms of ingestion of drugs such as Cannabis or 5ht2a agonists. The method of delivery/formulation selected from: Beverage (soda, water, tea, coffee, or other), Candy (gum, gummy, chocolate, hard candy, taffy, or other), Food, smoking, vaping, e-cigarette, vape-pen, bong, vaporizer, tab, geltab, blotter, sublingual strip.

Abstract: The invention involves the use of formulations of allosteric modulators of primarily 5ht2/tht1, CB1, serotonin transporter and opiate receptors/systems, but also those of: 5ht1a/b/c/d, 5ht2a/b/c, 5ht3, 5ht4, 5ht7, dopamine, and other receptors, used before, after or in combination with phenethylamines, tryptamines, ibogaloids and other compounds; to increase the effects of ingestion of drugs such as Cannabis or 5-ht2a agonists. The method of delivery/formulation selected from: Beverage (soda, water, tea, coffee, or other), Candy (gum, gummy, chocolate, hard candy, taffy, or other), Food, smoking, vaping, e-cigarette, vape-pen, bong, vaporizer.

Abstract: The invention involves the use of formulations of positive, negative or other allosteric modulators of primarily 5ht2a receptors, but also those of: 5ht1a/b/c/d, 5ht2b/c, 5ht3, 5ht4, 5ht7, and other receptors and systems, in combination with phenethylamines and other compounds; to treat nicotine dependency (addiction) such as tobacco-use (smoking, vaping, sublingual, oral) and/or tobacco smoking cessation.

Abstract: The invention involves the use of formulations of positive, negative or other allosteric modulators of primarily 5ht2a receptors, but also those of: 5ht1a/b/c/d, 5ht2b/c, 5ht3, 5ht4, 5ht7, and other receptors in combination with phenethylamines and other compounds; to treat brain cancer such as glioma(s) and/or glioblastoma(s).

Abstract: The invention involves the use of formulations of positive, negative, inverse agonist, or neutral allosteric modulators of receptors such as, but not limited to: 5ht1a/b/c/d, 5ht2a/b/c, 5ht3, 5ht4, 5ht5, 5ht6, 5ht7, dopamine receptors (D1, D2, D3, D4, D5), adrenergic receptors (?1A, ?1B, ?2A, ?2B, ?2C, ?1, ?2), serotonin transporter (SERT), DA transporter (DAT), norepinephrine transporter (NET), imidazolinel receptor (I1), Sigma receptors (?1, ?2), delta opioid receptor (DOR), kappa opioid receptor (KOR), mu opioid receptor (MOR), muscarinic receptors (M1, M2, M3, M4, M5), histamine receptors (H1, H2), calcium ion channel (Ca+) and N-methyl D-aspartate (NMDA) glutamate receptor; alone or in combination with items such as, but not limited to: cannabinoids, terpenes, flavonoids, minerals, psychedelic and psychoactive compounds such as, but not limited to 5ht2a receptor agonists or other compounds; for medical, recreational, religious, research and other uses.

Abstract: This present invention is directed to a method for the production and use of the leaf and/or leaves and/or stem(s) and/or stalk(s) of plants of the cannabis species for animal, microbial, bacteria, fungi or human consumption as a food, supplement, medicine, beverage.

Abstract: The invention involves the use of formulations of positive, negative, inverse agonist, or neutral allosteric modulators of receptors such as, but not limited to: 5ht1a/b/c/d, 5ht2a/b/c, 5ht3, 5ht4, 5ht5, 5ht6, 5ht7, dopamine receptors (D1, D2, D3, D4, D5), adrenergic receptors (?1A, ?1B, ?2A, ?2B, ?2C, ?1, ?2), serotonin transporter (SERT), DA transporter (DAT), norepinephrine transporter (NET), imidazoline1 receptor (I1), Sigma receptors (?1, ?2), delta opioid receptor (DOR), kappa opioid receptor (KOR), mu opioid receptor (MOR), muscarinic receptors (M1, M2, M3, M4, M5), histamine receptors (H1, H2), calcium ion channel (Ca+) and N-methyl D-aspartate (NMDA) glutamate receptor; alone or in combination with items such as, but not limited to: cannabinoids, terpenes, flavonoids, minerals, psychedelic and psychoactive compounds such as, but not limited to 5ht2a receptor agonists or other compounds; for medical, recreational, religious, research and other uses.

Abstract: The invention involves the breeding, seed multiplication, vegetative propagation and cultivation of: Cannabis sativa, Cannabis indica, Cannabis ruderalis, feral Cannabis, as well as all hybrids thereof to increase protein content, especially relating to portions of the plant aside from the seed. Further relating to processing, extraction, isolation of proteins from: Cannabis sativa, Cannabis indica, Cannabis ruderalis, feral Cannabis, as well as all hybrids thereof and especially relating to portions of the plant aside from the seed; and the use of these protein rich plant(s), plant part(s), extract(s), isolate(s), cosmetic(s), product(s) etc for medicines, foods, supplements, drinks for animals or humans as well as for use in plant, bacteria, fungi, lichen, algae cultivation.

Abstract: The invention involves the use of a combination of s-abscisic acid (S-ABA), methyl jasmonate (MJ), glucose, sucrose and fructose to raise the level of cannabinoids and terpenes (flavor and scent molecules) in the Cannabis Sativa plant.

Abstract: The invention involves the use of a combination of s-abscisic acid (S-ABA), methyl jasmonate (MJ), glucose, sucrose and fructose to raise the level of cannabinoids and terpenes (flavor and scent molecules) in the Cannabis Sativa plant.